为探究 Tarlatamab 治疗经治小细胞肺癌（SCLC）的患者报告结局（PROs），研究发现其有积极效益风险比，意义重大。 小细胞肺癌（Small Cell Lung Cancer，SCLC）是肺癌中一种极具侵袭性的类型，就像隐藏在身体里的 “恶魔”，无情地侵蚀着患者的健康。它的 5 年总生存 ...

The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...

The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as Imdyllytra, for the treatment of small cell lung cancer that has spread ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.

Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority review. Tarlatamab has been ...